CY1109404T1 - Μεθοδος δια την παρασκευη προϊοντων στεροειδους ορμονης. η οποια περιλαμβανει παραγοντα σταθεροποιησεως εις μη-κρυσταλλικην μορφη - Google Patents

Μεθοδος δια την παρασκευη προϊοντων στεροειδους ορμονης. η οποια περιλαμβανει παραγοντα σταθεροποιησεως εις μη-κρυσταλλικην μορφη

Info

Publication number
CY1109404T1
CY1109404T1 CY20091101002T CY091101002T CY1109404T1 CY 1109404 T1 CY1109404 T1 CY 1109404T1 CY 20091101002 T CY20091101002 T CY 20091101002T CY 091101002 T CY091101002 T CY 091101002T CY 1109404 T1 CY1109404 T1 CY 1109404T1
Authority
CY
Cyprus
Prior art keywords
crystal form
products
includes stabilization
hormone
steroid products
Prior art date
Application number
CY20091101002T
Other languages
English (en)
Inventor
Thomas Schultz
Bradley A Clark
Angela Falzone
Original Assignee
Ortho-Mcneil-Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil-Janssen Pharmaceuticals, Inc. filed Critical Ortho-Mcneil-Janssen Pharmaceuticals, Inc.
Publication of CY1109404T1 publication Critical patent/CY1109404T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεσις αναφέρεται εις προϊόντα στεροειδούς ορμόνης, όπως από του στόματος αντισυλληπτικά προϊόντα, τα οποία περιλαμβάνουν τουλάχιστον ένα στεροειδές δραστικόν συστατικόν εν αναμίξει μετ'εκδόχου και τα οποία έχουν βελτιωμένας ιδιότητας διαλύσεως και ταχύτητος απελευθερώσεως. Η εφεύρεσις αναφέρεται εις μεθόδους δια παρασκευήν τοιούτων προϊόντων στεροειδούς ορμόνης, ένθα μίγμα της ορμόνης και του εκδόχου υποβάλλεται εις επαρκήν μηχανικήν ενέργεια προς διαμόρφωσιν κονιώδους μίγματος (μίγματος κόνεως) εις το οποίον η ορμόνη σταθεροποιείται υπό του εκδόχου εις ουσιωδώς μη-κρυσταλλικήν μορφή.
CY20091101002T 2000-12-14 2009-09-24 Μεθοδος δια την παρασκευη προϊοντων στεροειδους ορμονης. η οποια περιλαμβανει παραγοντα σταθεροποιησεως εις μη-κρυσταλλικην μορφη CY1109404T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25566900P 2000-12-14 2000-12-14
EP05076805A EP1591121B1 (en) 2000-12-14 2001-12-13 Process for preparing steroid hormone products comprising a stabilizing agent in non-crystalline form

Publications (1)

Publication Number Publication Date
CY1109404T1 true CY1109404T1 (el) 2014-07-02

Family

ID=22969374

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101002T CY1109404T1 (el) 2000-12-14 2009-09-24 Μεθοδος δια την παρασκευη προϊοντων στεροειδους ορμονης. η οποια περιλαμβανει παραγοντα σταθεροποιησεως εις μη-κρυσταλλικην μορφη

Country Status (31)

Country Link
US (4) US7867990B2 (el)
EP (2) EP1591121B1 (el)
KR (1) KR100899032B1 (el)
CN (1) CN1290507C (el)
AT (2) ATE307591T1 (el)
AU (2) AU2742102A (el)
BG (1) BG66178B1 (el)
BR (1) BRPI0116793B8 (el)
CA (1) CA2431521E (el)
CR (1) CR7022A (el)
CY (1) CY1109404T1 (el)
CZ (1) CZ306435B6 (el)
DE (2) DE60139087D1 (el)
DK (2) DK1361881T3 (el)
EC (1) ECSP034654A (el)
EE (1) EE05358B1 (el)
ES (2) ES2253451T3 (el)
HK (2) HK1057174A1 (el)
HU (1) HU230400B1 (el)
IL (2) IL156423A0 (el)
ME (1) ME00339B (el)
MX (1) MXPA03005339A (el)
NO (2) NO334341B1 (el)
NZ (1) NZ526517A (el)
PT (1) PT1591121E (el)
RS (1) RS50414B (el)
RU (1) RU2286155C2 (el)
SK (1) SK288222B6 (el)
UA (1) UA77404C2 (el)
WO (1) WO2002047693A2 (el)
ZA (1) ZA200305342B (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
CA2431521E (en) * 2000-12-14 2013-04-16 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products and methods for preparing them
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
DK1844765T3 (en) * 2003-06-13 2015-04-27 Skendi Finance Ltd Slow release estradiol progesterone formulation
US8101244B2 (en) 2004-06-09 2012-01-24 Smithkline Beecham Corporation Apparatus and method for producing or processing a product or sample
TWI547431B (zh) 2004-06-09 2016-09-01 史密斯克萊美占公司 生產藥物之裝置及方法
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
CN101939009B (zh) * 2008-02-05 2013-07-17 哈博生物科学公司 药学固体形式
US8252947B2 (en) * 2008-04-03 2012-08-28 Harbor Therapeutics, Inc. Solid state forms of a pharmaceutical
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
US10993879B2 (en) 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
ES2773079T3 (es) * 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
CN102793929B (zh) * 2012-09-07 2013-12-11 上海奥科达生物医药科技有限公司 一种制备稳定非晶态药物制剂的方法
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US20200129438A1 (en) * 2018-10-31 2020-04-30 Edenbridge Pharmaceuticals, LLC Finished pharmaceutical dosage form comprising a low dose/high potency active pharmaceutical ingredient and one or more excipients
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2648700A (en) * 1946-11-02 1953-08-11 Searle & Co 2-methyl-2,7-dihydroxy-octahydrophenanthrene-1-propionic acid and derivatives thereof
US2636042A (en) * 1949-07-08 1953-04-21 S B Penick And Company Water-soluble hormone compounds
US2642427A (en) * 1951-08-01 1953-06-16 Abbott Lab Piperazine salts of cyclopentanopolyhydrophenanthrene-3-monosulfates
US2666066A (en) * 1951-09-28 1954-01-12 Abbott Lab Ethylenediamine salts of cyclopen-tanopolyhydrophenanthrene-3-monosulfates
US3032469A (en) * 1958-05-02 1962-05-01 Charles E Frosst & Company Long acting steroid compounds
US3568828A (en) * 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3691212A (en) * 1970-04-24 1972-09-12 British Drug Houses Ltd 17alpha-(1',3'-alkadiynyl)-17beta-acyloxy(17beta-aroyloxy) steroids
US4046874A (en) * 1974-02-13 1977-09-06 Mead Johnson & Company Soapless shave composition
US4511551A (en) * 1982-11-18 1985-04-16 Unique Technologies, Incorporated Method and composition for the detection of a precancerous or leukemic condition in mammals
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
EP0193871B1 (en) * 1985-03-07 1989-05-31 Teikoku Hormone Mfg. Co., Ltd. 2-oxa- or aza-pregnane compounds
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
US5344392A (en) * 1990-09-28 1994-09-06 Baxter International Inc. Method and apparatus for preparation of solutions from concentrates
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
DE69207863T2 (de) * 1991-11-13 1996-06-05 Glaxo Canada Vorrichtung zur kontrollierten Wirkstoffreigabe
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
IT1270831B (it) * 1993-09-17 1997-05-13 Romano Deghenghi Composizioni farmaceutiche orali effervescenti contenenti estrone
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
AR004178A1 (es) 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
JP2000515890A (ja) * 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション プロゲスチンとエストロゲンとの混合剤からなる一相性避妊法およびキット
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6190693B1 (en) * 1998-04-17 2001-02-20 Ortho-Mcneil Pharamceutical, Inc. Pharmaceutical methods of delivering folic acid
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6667050B1 (en) * 1999-04-06 2003-12-23 Galen (Chemicals) Limited Chewable oral contraceptive
CA2431521E (en) * 2000-12-14 2013-04-16 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products and methods for preparing them

Also Published As

Publication number Publication date
CZ306435B6 (cs) 2017-01-25
SK288222B6 (sk) 2014-09-04
EE05358B1 (et) 2010-12-15
HK1083457A1 (en) 2006-07-07
AU2742102A (en) 2002-06-24
NO20032708D0 (no) 2003-06-13
NZ526517A (en) 2005-09-30
ATE434439T1 (de) 2009-07-15
ECSP034654A (es) 2003-07-25
PT1591121E (pt) 2009-07-20
YU47903A (sh) 2006-08-17
UA77404C2 (en) 2006-12-15
US20110046099A1 (en) 2011-02-24
EP1361881A2 (en) 2003-11-19
WO2002047693A2 (en) 2002-06-20
CR7022A (es) 2009-02-23
KR100899032B1 (ko) 2009-05-21
DE60114467D1 (de) 2005-12-01
WO2002047693A3 (en) 2002-11-07
ZA200305342B (en) 2004-10-11
RS50414B (sr) 2009-12-31
ATE307591T1 (de) 2005-11-15
ME00339B (me) 2011-05-10
HU230400B1 (hu) 2016-04-28
US7867990B2 (en) 2011-01-11
BG66178B1 (bg) 2011-11-30
BR0116793A (pt) 2004-01-27
EP1361881B1 (en) 2005-10-26
MEP48808A (en) 2011-02-10
US20110046095A1 (en) 2011-02-24
EE200300229A (et) 2003-08-15
HUP0400646A3 (en) 2012-08-28
DE60114467T2 (de) 2006-07-20
IL156423A (en) 2010-04-29
IL156423A0 (en) 2004-01-04
CA2431521A1 (en) 2002-06-20
DK1591121T3 (da) 2009-10-05
KR20030061856A (ko) 2003-07-22
NO20032708L (no) 2003-07-04
MXPA03005339A (es) 2004-03-26
BG107958A (bg) 2004-11-30
RU2286155C2 (ru) 2006-10-27
US20140309204A1 (en) 2014-10-16
HK1057174A1 (en) 2004-03-19
ES2327538T3 (es) 2009-10-30
ES2253451T3 (es) 2006-06-01
NO334341B1 (no) 2014-02-10
HUP0400646A2 (hu) 2004-06-28
EP1591121B1 (en) 2009-06-24
CN1489468A (zh) 2004-04-14
BRPI0116793B8 (pt) 2021-05-25
AU2002227421B2 (en) 2007-08-23
BRPI0116793B1 (pt) 2015-06-23
SK8802003A3 (en) 2004-04-06
RU2003121240A (ru) 2005-02-10
DK1361881T3 (da) 2006-02-20
CZ20031896A3 (en) 2004-03-17
CA2431521C (en) 2010-03-16
DE60139087D1 (de) 2009-08-06
EP1591121A1 (en) 2005-11-02
NO20131334L (no) 2003-07-04
CA2431521E (en) 2013-04-16
CN1290507C (zh) 2006-12-20
US20020173669A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
CY1109404T1 (el) Μεθοδος δια την παρασκευη προϊοντων στεροειδους ορμονης. η οποια περιλαμβανει παραγοντα σταθεροποιησεως εις μη-κρυσταλλικην μορφη
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
YU69603A (sh) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
PT1412384E (pt) Formulação estável de glp-1 modificado
CY1109567T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν δροσπιρενονη
FI971172A (fi) Menetelmä annosyksikköjen valmistamiseksi märkärakeistamalla
LU91433I2 (fr) "Tenofovir disoproxil et les sels, en particulier le fumarate, hydrates, tautomers et solvates en combination avec l'emtricitabine et l'efavirenz (ATRIPLA)
DK0680326T3 (da) Farmaceutisk formulering af nikotinafhængighed.
BRPI0014142B8 (pt) composição de vacina comprimida estável, e, pacote para vacinação
BG106417A (en) Vaccine
AR021806A1 (es) COMPOSICIoN FARMACÉUTICA EN FORMA DE TABLETA QUE COMPRENDE ENTACAPONA Y MÉTODO DE PREPARACIoN.
EP0682942A4 (en) NEW ABSORBABLE PERCUTANEOUS PREPARATION.
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
IL93599A0 (en) Kit and/or composition for the prevention or treatment of aids
ZA200100289B (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis.